January 27th 2022 : Newsletter
Upperton is pleased to announce that it has bolstered its nasal and oral delivery capabilities with the addition of a number of new analytical and formulation technologies.
Nasal Delivery News – Upperton enhances its analytical capabilities by acquiring next generation nasal particle impaction technology
Upperton has acquired the Copley Alberta Idealised Nasal Inlet (AINI) device to enable its scientists to generate representative deposition data for new drug formulations within the nasal airways. Indeed, understanding the aerodynamic properties of drugs delivered to the nose is a critical aspect when evaluating the performance of new liquid and powder formulations as well as a future regulatory requirement.
When developing a formulation for nasal delivery (liquid or powder) it is important to optimise and measure regional deposition of the drug formulation delivered from the device. This is important in order to maximise the fraction of drug absorbed via the target pathway. It is also important from a safety and a regulatory perspective to measure and ultimately to minimise drug transit to the lungs.
Whilst laser-based particle/droplet sizing techniques (eg Sympatec™, Malvern SprayTec™) will generate actual geometric size distributions, data generated in this way does not take into account device performance and the aerodynamic properties of the particles/droplets leaving the device at the point of delivery into the nose. Both of these factors are critical and will ultimately determine where deposition will take place for these nasally inhaled products.
Using more realistic nasal models enables a more representative assessment of drug delivery performance in relation to the target site The Copley AINI enables representative testing of the deposition of drug within the nasal airways, a key factor when engineering formulations that target different parts of the nasal passage, depending on the ultimate route of delivery for the API in question.